Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Mayo Clinic
Ohio State University Comprehensive Cancer Center
University of California, Irvine
Emory University
Institute of Oncology Ljubljana
Ohio State University Comprehensive Cancer Center
Duke University
Institute of Oncology Ljubljana
Melanoma Institute Australia
Essen Biotech
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
University of California, Davis
Instituto do Cancer do Estado de São Paulo
City of Hope Medical Center
University of Pittsburgh
Mayo Clinic
NuCana plc
M.D. Anderson Cancer Center
University of Southern California
Brown University
Melanoma Institute Australia
M.D. Anderson Cancer Center
University of Pittsburgh
University of Chicago
Memorial Sloan Kettering Cancer Center
Yale University
Institut Curie
M.D. Anderson Cancer Center
Seattle Children's Hospital
University of Pittsburgh
Mayo Clinic
Grupo Español Multidisciplinar de Melanoma
Intergruppo Melanoma Italiano
Yale University
Emory University
Herlev Hospital
Providence Health & Services
NuCana plc
Mayo Clinic
Mayo Clinic
University of Chicago
Thomas Jefferson University
University of Pittsburgh
University of Florida
University Health Network, Toronto
Providence Health & Services
The Methodist Hospital Research Institute
Dana-Farber Cancer Institute